Cellectis S.A.
CLLSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of. The $365.2M market capitalization puts CLLS squarely in small-cap range for its industry. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Market Cap
$365.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-5.85
EPS (TTM)
$-0.67
EPS (Fwd)
$-0.62
ROE
-76.3%
ROA
-8.4%
Cash
$34.8M
Total Debt
$32.2M
Free CF
-$53.6M
52W Change
152.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $34.8M in cash comfortably exceeding the $32.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$53.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -76.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $19.2M (2022) to $72.9M (2025), reflecting a 281% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CLLS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.